Floatz logo

ANTI-TRAIL-R2 MOAB

Hepatic Cancer

Daiichi Sankyomonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Hepatic Cancer cohort.

Asset / SponsorPhaseRating
Tranexamic Acid
Konkuk University Medical Center
Phase 4BB
Recombinant Human Thrombopoietin
St. Jude Children's Research Hospital
Phase 1/2CCC
flt3 ligand
Celldex Therapeutics
Phase 1CC
IPIVIVINT
Biosplice Therapeutics, Inc.
Phase 1CC
CDX 1140
Celldex Therapeutics
Phase 1CC

View all 9 →

Same molecule, other indications

ANTI-TRAIL-R2 MOAB is also rated in:

breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
ovarian cancerDormant
B
Indicative ·
57 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →